Table 1.
Baseline demographic and clinical characteristics, by concomitant DPPIVi use (pooled randomised population).
Table 2.
Type of concomitant DPPIVi therapy used (pooled randomised population).
Fig 1.
HbA1c (mean ± SE) during 6 months of treatment, by visit and DPPIVi use (pooled mITT population).
Data are pooled from EDITION 2 and EDITION 3. CI, confidence interval; DPPIVi, dipeptidyl peptidase IV inhibitor; LS, least squares; mITT, modified intention-to-treat; SE, standard error.
Fig 2.
Cumulative mean number of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemic events per participant, by DPPIVi use: (a) nocturnal (00:00–05:59 h) events; (b) any time of day (24 h) events (pooled safety population). Data are pooled from EDITION 2 and EDITION 3. DPPIVi, dipeptidyl peptidase IV inhibitor.
Fig 3.
Confirmed or severe hypoglycaemia over 6 months, by DPPIVi use (pooled safety population).
Data are pooled from EDITION 2 and EDITION 3. CI, confidence interval; DPPIVi, dipeptidyl peptidase IV inhibitor; RR, relative risk for participants with ≥1 event or rate ratio for events per participant-year.